Published by Iain Gilbert on 27th January 2020
(Sharecast News) - Drugs developer Shield Therapeutics told investors on Monday that 2019 had been a year of "material progress", with a key success being the recent Federal Drug Administration approval of its iron deficiency treatment, Feraccru/Accrufer.
URL: http://www.digitallook.com/dl/news/story/30161027/...